Stryker Corporation (SYK) Stock Price & Analysis
Stryker Corporation (SYK) closed at USD 307.08 on Thursday, October 22, 2026, up 3.19% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 297.6; the Oct 22, 2026 session ranged USD 299.36–309.67 on volume of 2,804,649 shares. Market capitalization is $117.79B, with a 52-week range of USD 267–389.33 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:23 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SYK.md
Key facts (SYK)
- Last four reported quarters (through Jun 30, 2026): revenue $25.8B, net income $3.73B (14.4% margin), free cash flow $4.70B (SEC filings).
- Valuation: P/E 31.6x (avg 41.5x at the last 3 fiscal year-ends), EV/EBITDA 18.1x, net debt $11.5B.
- 4 of 80 tracked superinvestors hold SYK (13F, Q2 2026): 0 new, 0 added, 4 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 6 Form 4 filings, $219M; 5 not under a Rule 10b5-1 plan ($217M); 3 by opportunistic insiders (2 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $27K.
- Analysts: Buy (mean 1.93 on a 1–5 scale) (29 analysts), mean target USD 362.62 (range 298–465).
- Total return with dividends: 1Y -18.9% vs S&P 500 +14.9%; 5Y +17.4% vs S&P 500 +80.3%.
- Next earnings: 2026-10-29, EPS estimate USD 3.55, revenue estimate $6.62B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (SYK)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $17.1B | $18.4B | $20.5B | $22.6B | $25.1B | $25.8B |
| Gross profit | $11.0B | $11.6B | $13.1B | $14.4B | $16.1B | — |
| Operating income | $2.58B | $2.84B | $3.89B | $3.69B | $4.89B | $5.53B |
| Net income | $1.99B | $2.36B | $3.17B | $2.99B | $3.25B | $3.73B |
| EPS (diluted) | $5.21 | $6.17 | $8.25 | $7.76 | $8.40 | — |
| Free cash flow | $2.74B | $2.04B | $3.14B | $3.49B | $4.28B | $4.70B |
| Gross margin | 64.1% | 62.8% | 63.7% | 63.9% | 64.0% | — |
| Operating margin | 15.1% | 15.4% | 19.0% | 16.3% | 19.5% | 21.4% |
| Net margin | 11.7% | 12.8% | 15.4% | 13.2% | 12.9% | 14.4% |
| Revenue growth | +19.2% | +7.8% | +11.1% | +10.2% | +11.2% | — |
| Cash + short-term investments | $3.02B | $1.93B | $3.05B | $3.74B | $4.10B | — |
| Total debt | $12.5B | $13.0B | $13.0B | $13.6B | $15.9B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (SYK)
P/E 31.6x · P/S 4.6x · EV/EBITDA 18.1x · EV/Sales 5.0x · P/FCF 25.1x · P/B 4.9x · FCF yield 3.99% · Earnings yield 3.17% · Dividend yield (paid, TTM) 1.12% · Net debt $11.5B · EV $129B
P/E at fiscal year-ends: Dec 2025 41.8x, Dec 2024 46.4x, Dec 2023 36.3x.
Superinvestors (SEC 13F-HR, Q2 2026) (SYK)
4 of 80 tracked investors hold SYK. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Terry Smith | Fundsmith | 6.72% | $917M | Reduced -4.8% |
| Jensen Investment Management | 4.50% | $186M | Reduced -15.3% | |
| AKO Capital | 0.15% | $6.5M | Reduced -91.8% | |
| Mairs & Power | Mairs & Power Funds | 0.01% | $1.3M | Reduced -2.0% |
Insider sales (SEC Form 4, open-market, last ~7 months) (SYK)
1 of 6 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-21 | Crotty Dylan Bram | Group President | 441 | $145K | 3.1% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-18…2026-08-19 | Stryker Ronda E | Director | 350,000 | $118M | 2.4% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-08-18 | King Debra | See Remarks | 826 | $278K | 11.7% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-28 | Fletcher Robert S | VP, Chief Legal Officer | 4,544 | $1.4M | 29.7% | Yes (adopted February 26, 2026) | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-05-26 | Stryker Ronda E | Director | 310,000 | $96.8M | 2% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-05-11 | Fink M Kathryn | VP, Chief HR Officer | 8,720 | $2.5M | 38.8% | No | Too little history (no open-market trades in 2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Insider purchases (SEC Form 4, open-market, last ~7 months) (SYK)
1 purchase, $27K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price |
|---|---|---|---|---|---|
| 2019-06-26…2022-11-22 | Brainerd Mary K | Director | 131 | $27K | 204.09 |
Analysts (SYK)
Consensus Buy (mean 1.93 on a 1–5 scale), 29 analysts; mean target USD 362.62 (low 298, high 465).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | BTIG | Target lowered | Buy | $358 → $316 |
| 2026-10-07 | Truist Securities | Target lowered | Hold | $340 → $310 |
| 2026-10-07 | Barclays | Initiated | Overweight | $375 |
| 2026-09-30 | Stifel | Target lowered | Buy | $360 → $330 |
| 2026-09-22 | TD Cowen | Target lowered | Hold | $355 → $298 |
| 2026-09-18 | Canaccord Genuity | Target lowered | Buy | $400 → $385 |
| 2026-09-10 | Citigroup | Target lowered | Buy | $399 → $360 |
| 2026-09-09 | Wells Fargo | Target lowered | Overweight | $418 → $348 |
| 2026-08-13 | Wolfe Research | Downgrade | Outperform → Peer Perform | |
| 2026-08-03 | Citizens | Target lowered | Market Outperform | $440 → $400 |
| 2026-07-31 | RBC Capital | Target lowered | Outperform | $435 → $420 |
| 2026-07-31 | JP Morgan | Target lowered | Overweight | $400 → $350 |
Total return (dividends reinvested) (SYK)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -18.9% | +17.4% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -19.0% | +3.3% |
| Volatility (annualized) | 30.5% | 25.1% |
| Max drawdown | -30.0% (Feb 2026→Sep 2026) | -31.8% (Jul 2025→Sep 2026) |
SYK revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| MedSurg and Neurotechnology: | $3.63B | 55.0% | +9.7% |
| Orthopaedics: | $2.96B | 45.0% | +9.1% |
| Orthopaedics | $2.96B | 45.0% | +9.1% |
| Total revenue | $6.59B | 100% | — |
SYK revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Medical | $1.12B | 17.0% | +13.3% |
| Traumaand Extremities | $1.07B | 16.3% | +12.0% |
| Endoscopy | $1.00B | 15.2% | +11.7% |
| Instruments | $1.00B | 15.2% | +9.3% |
| Ortho Tech | $717.0M | 10.9% | +10.5% |
| Knees | $693.0M | 10.5% | +8.3% |
| Neuro Cranial Instruments | $681.0M | 10.3% | +10.6% |
| Orthopaedic Instruments | $523.0M | 7.9% | +4.4% |
| Neurovascular | $496.0M | 7.5% | -0.4% |
| Hips | $479.0M | 7.3% | +2.8% |
| Other Orthopedics | $194.0M | 2.9% | +31.1% |
| Enabling Technologies | $28.0M | 0.4% | -17.6% |
| Spinal Implants | $3.0M | 0.0% | -40.0% |
| Total revenue | $6.59B | 100% | — |
SYK revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $4.96B | 75.3% | +8.9% |
| International | $1.63B | 24.7% | +11.0% |
| Total revenue | $6.59B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
Companies that name SYK in their SEC reports
| Relationship to SYK | Company | Filing | Sentence |
|---|---|---|---|
| partner | Xtant Medical Holdings, Inc. (XTNT) | 10-K Mar 31, 2026 | “Inc., RegionalCare Hospital Partners, Wright Medical Group, Inc., which was acquired by Stryker Corporation (NYSE: SYK) in November 2020,” |
| partner | SBC Medical Group Holdings Inc (SBC) | 10-K Mar 27, 2026 | “Braun SE, Cynosure Lutronic, Evolus, Inc., Galderma S.A., Genesis Biosystems, Inc., Inmode Ltd., IRIDEX Corporation, Lumenis Be Ltd., Sinclair Pharma Limited, Stryker Corporation, and Surgery Partners.” |
SYK company outlook (results filed Jul 30, 2026)
- “We are narrowing our full year 2026 guidance and now expect organic net sales growth (2) in the range of 8.3% to 9.3% and adjusted net earnings per diluted share (2) in the range of $14.95 to $15.10.”
- “Additionally, foreign exchange is expected to have a slightly favorable impact on both sales and adjusted net earnings per diluted share (2) should rates hold near current levels.”
- “(2) We are unable to present a quantitative reconciliation of our expected net sales growth to expected organic net sales growth as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of acquisitions and divestitures and the impact of foreign currency exchange rates.”
Quoted word-for-word from the SEC 8-K results press release.
SYK analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $3.55 | $3.68 | -3.7% | $6.62B | 25 |
| Next quarter (ends Dec 2026) | $5.12 | $5.18 | -1.2% | $7.96B | 24 |
| Current fiscal year (ends Dec 2026) | $14.95 | $14.98 | -0.2% | $27.17B | 28 |
| Next fiscal year (ends Dec 2027) | $16.66 | $16.72 | -0.3% | $29.49B | 28 |
Key Statistics (as of October 23, 2026 at 09:23 UTC)
| Price | USD 307.08 |
|---|---|
| Change | ▲ 3.19% (up) |
| Previous Close | USD 297.6 |
| Open | USD 299.8 |
| Day Range | USD 299.36 – 309.67 |
| 52-Week Range | USD 267 – 389.33 |
| Volume | 2,804,649 shares |
| Market Cap | $117.79B |
| Exchange | NYQ |
Technical Analysis (SYK)
Nexqual's technical model rates SYK "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:23 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 62.44 (neutral) |
| vs SMA50 | Above (USD 296.48) |
| MACD | 2.91 (positive) |
Analyst Ratings (SYK)
Wall Street analysts rate SYK "Buy" based on 29 analysts, with a mean price target of USD 362.62 (range USD 298–465), per Nexqual as of October 23, 2026 at 09:23 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 29 |
| Mean Target | USD 362.62 |
| High Target | USD 465 |
| Low Target | USD 298 |
| Buy / Hold / Sell | 23 / 6 / 0 |
Earnings (SYK)
| Next Earnings Date | 2026-10-29 |
|---|---|
| EPS Estimate | USD 3.55 |
| Revenue Estimate | $6.62B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 3.69 vs est 3.49 ▲ beat |
| 2026-03-31 | USD 2.6 vs est 2.98 ▼ miss |
| 2025-12-31 | USD 4.47 vs est 4.4 ▲ beat |
| 2025-09-30 | USD 3.19 vs est 3.13 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financials & Fundamentals (SYK)
| Total Revenue | $25.84B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +9.40% |
| Gross Margin | +65.59% |
| Operating Margin | +27.02% |
| Profit Margin | +14.43% |
| ROE | +16.51% |
| Debt / Equity | 0.64 |
| Current Ratio | 2.16 |
| Total Cash | $3.48B |
| Total Debt | $15.45B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $4.70B (18.2% of revenue) |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financial Health Score (SYK)
Nexqual rates Stryker Corporation's overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:23 UTC.
| Growth | Solid — Revenue +11% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 66%, operating 27% (last 12 months) |
| Balance Sheet | Strong — $3.48B cash and investments vs $14.9B debt (Jun 2026, SEC) |
| Cash Flow | Strong — FCF $4.70B (last 4 quarters to Jun 2026, SEC), 18% margin |
| Efficiency | Solid — ROE 17%, ROA 8.2% |
Ownership (SYK)
| Insider Ownership | +5.36% |
|---|---|
| Institutional Ownership | +83.03% |
| Shares Outstanding | 383.57M |
| Float | 348.14M |
| Short % of Float | +1.56% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Leadership (SYK)
Stryker Corporation is led by Kevin A. Lobo, Chairman & CEO, per Nexqual as of October 23, 2026 at 09:23 UTC.
| Chairman & CEO | Kevin A. Lobo |
|---|---|
| President & COO | Spencer S. Stiles |
| VP & CFO | Preston W. Wells |
| Group President of Global Quality & Operations | Viju S. Menon |
| Group President of MedSurg & Neurotechnology | J. Andrew Pierce |
Major Backers & Investors (SYK)
Notable institutional backers of Stryker Corporation include JPMorgan, Greenleaf Trust, Price (T.Rowe) Associates Inc, according to Nexqual as of October 23, 2026 at 09:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| JPMorgan | 4.5% |
| Greenleaf Trust | 3.97% |
| Price (T.Rowe) Associates Inc | 3.11% |
| Wellington Management | 2.13% |
| Morgan Stanley | 1.55% |
| Fidelity | 1.17% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.01% |
| BlackRock | 7.15% |
| State Street | 4.05% |
| Geode Capital | 2.04% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MDT | Medtronic plc. | USD 96.59 | ▲ 3.83% |
| ABT | Abbott Laboratories | USD 102.51 | ▲ 1.99% |
| BSX | Boston Scientific Corporation | USD 46.01 | ▲ 3.37% |
| EW | Edwards Lifesciences Corporatio | USD 90.09 | ▲ 1.91% |
| GEHC | GE HealthCare Technologies Inc. | USD 71.42 | ▲ 3.49% |
| DXCM | DexCom, Inc. | USD 78.32 | ▼ 2.42% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:23 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt